Tempus AI, Inc. $TEM Shares Sold by Victory Financial Group LLC

Victory Financial Group LLC trimmed its holdings in Tempus AI, Inc. (NASDAQ:TEM) by 45.2% in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 15,000 shares of the company’s stock after selling 12,377 shares during the period. Victory Financial Group LLC’s holdings in Tempus AI were worth $1,228,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds have also modified their holdings of the business. Guardian Partners Inc. boosted its position in Tempus AI by 8.3% during the third quarter. Guardian Partners Inc. now owns 2,600 shares of the company’s stock worth $213,000 after acquiring an additional 200 shares during the last quarter. V Square Quantitative Management LLC acquired a new stake in Tempus AI in the 3rd quarter valued at about $27,000. Cyndeo Wealth Partners LLC raised its holdings in Tempus AI by 6.7% in the 3rd quarter. Cyndeo Wealth Partners LLC now owns 6,412 shares of the company’s stock valued at $525,000 after acquiring an additional 400 shares during the last quarter. Arkadios Wealth Advisors raised its holdings in Tempus AI by 9.6% in the 1st quarter. Arkadios Wealth Advisors now owns 4,963 shares of the company’s stock valued at $224,000 after acquiring an additional 435 shares during the last quarter. Finally, GAMMA Investing LLC raised its holdings in Tempus AI by 54.3% in the 3rd quarter. GAMMA Investing LLC now owns 1,239 shares of the company’s stock valued at $101,000 after acquiring an additional 436 shares during the last quarter. 24.22% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In related news, CEO Ryan Fukushima sold 41,095 shares of the firm’s stock in a transaction dated Tuesday, August 18th. The stock was sold at an average price of $49.61, for a total transaction of $2,038,722.95. Following the completion of the sale, the chief executive officer directly owned 562,463 shares of the company’s stock, valued at approximately $27,903,789.43. This trade represents a 6.81% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Eric Lefkofsky sold 250,000 shares of the business’s stock in a transaction dated Tuesday, September 22nd. The shares were sold at an average price of $77.47, for a total transaction of $19,367,500.00. Following the completion of the sale, the chief executive officer owned 100,000 shares in the company, valued at approximately $7,747,000. This trade represents a 71.43% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders have sold 1,030,965 shares of company stock valued at $69,882,564. 24.26% of the stock is owned by company insiders.

Analysts Set New Price Targets

TEM has been the topic of several recent research reports. Guggenheim boosted their target price on Tempus AI from $65.00 to $92.00 and gave the stock a “buy” rating in a report on Thursday, October 1st. Rothschild & Co Redburn assumed coverage on Tempus AI in a report on Tuesday, September 8th. They issued a “neutral” rating and a $67.00 price target for the company. Wall Street Zen raised Tempus AI from a “sell” rating to a “hold” rating in a report on Saturday, July 25th. Raymond James Financial set a $80.00 price objective on Tempus AI in a research report on Wednesday, September 2nd. Finally, Canaccord Genuity Group lifted their price objective on Tempus AI from $80.00 to $95.00 and gave the stock a “buy” rating in a research report on Monday, October 12th. Eleven investment analysts have rated the stock with a Buy rating, nine have issued a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Hold” and an average price target of $72.47.

Tempus AI News Summary

Here are the key news stories impacting Tempus AI this week:

• Positive Sentiment: Large Bristol Myers Squibb and Pathos agreement: Tempus disclosed agreements expected to provide approximately $192.5 million in aggregate cash payments over about five years. The oncology portion gives Bristol Myers Squibb access to Tempus’ multimodal oncology data, Lens software and related analytical services through 2031, strengthening the company’s recurring data and applications revenue outlook. Tempus AI Gains After New Bristol Myers Deal and EU Diagnostic Certification
• Positive Sentiment: European regulatory milestone: Tempus’ xR RNA-sequencing assay received EU IVDR Class C certification for solid-tumor genomic profiling. The certification may support broader adoption of the diagnostic in Europe and enhance the credibility of Tempus’ clinical testing business. Tempus Receives IVDR Certification for xR RNA Sequencing
• Positive Sentiment: Analyst support and earnings expectations: BTIG reaffirmed its buy rating and an $80 price target. Analysts are also expecting Tempus to potentially exceed consensus estimates in the upcoming report, which could provide another catalyst if revenue growth and cash management meet expectations. Tempus AI Expected to Beat Earnings Estimates
• Neutral Sentiment: Personalis acquisition remains an important uncertainty: Tempus has a pending approximately $1.5 billion deal for Personalis. Investors may look to the earnings report for updates on closing, financing and the strategic benefits of the transaction. The $1.5 Billion Question Facing Tempus AI Ahead of Nov. 2 Earnings
• Negative Sentiment: Profitability and dilution concerns persist: Tempus remains unprofitable, and continued cash burn could pressure the valuation or require additional financing. In addition, reported insider activity over the past six months consisted entirely of sales, including substantial selling by senior executives, which may weigh on investor sentiment. What Happens To Tempus AI Stock If Its Cash Burn Continues?

Tempus AI Stock Performance

Shares of Tempus AI stock opened at $72.15 on Wednesday. The firm has a market capitalization of $13.02 billion, a price-to-earnings ratio of -50.10 and a beta of 3.54. Tempus AI, Inc. has a fifty-two week low of $40.77 and a fifty-two week high of $92.00. The stock has a 50 day moving average of $69.70 and a 200 day moving average of $56.95.

Tempus AI (NASDAQ:TEM) last posted its earnings results on Thursday, July 30th. The company reported ($0.04) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.14) by $0.10. The business had revenue of $382.49 million for the quarter, compared to analyst estimates of $379.69 million. During the same period last year, the business earned ($0.22) EPS. Tempus AI’s revenue was up 21.6% compared to the same quarter last year. Analysts forecast that Tempus AI, Inc. will post -1.43 EPS for the current year.

About Tempus AI

Tempus AI, Inc is a healthcare technology company that uses artificial intelligence and data analytics to support precision medicine. The company combines clinical, molecular and imaging data to help physicians make more informed treatment decisions and to help researchers and biopharmaceutical companies develop therapies.

Its offerings include genomic testing and analysis, such as tissue- and blood-based tests, as well as software tools designed to assist with clinical decision-making, patient matching for clinical trials and the management of healthcare data.